Abstract
Accumulating evidence has reached the consensus that the balance of phosphorylation state of signaling molecules is a pivotal point in the regulation of cell signaling. Therefore, characterizing elements (kinases–phosphatases) in the phosphorylation balance are at great importance. However, the role of phosphatase enzymes is less investigated than kinase enzymes. PP2A is a member of serine/threonine protein phosphatase that its imbalance has been reported in neurodegenerative diseases. Therefore, we reviewed the superfamily of phosphatases and more specifically PP2A, its regulation, and physiological functions participate in CNS. Thereafter, we discussed the latest findings about PP2A dysregulation in Alzheimer and Parkinson diseases and possible interplay between this phosphatase and insulin signaling pathways. Finally, activating/inhibitory modulators for PP2A activity as well as experimental methods for PP2A study have been reviewed.
Similar content being viewed by others
References
Kurosawa M (1994) Phosphorylation and dephosphorylation of protein in regulating cellular function. J Pharmacol Toxicol Methods 31:135–139. https://doi.org/10.1016/1056-8719(94)90075-2
Novak B, Kapuy O, Domingo-Sananes MR, Tyson JJ (2010) Regulated protein kinases and phosphatases in cell cycle decisions. Curr Opin Cell Biol 22(6):801–808. https://doi.org/10.1016/j.ceb.2010.07.001
Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T (2004) Protein tyrosine phosphatases in the human genome. Cell 117(6):699–711. https://doi.org/10.1016/j.cell.2004.05.018
Mustelin T (2007) A brief introduction to the protein phosphatase families. Protein Phosphatase Protoc. https://doi.org/10.1385/1-59745-267-x:9
He RJ, Yu ZH, Zhang RY, Zhang ZY (2014) Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin 35(10):1227–1246. https://doi.org/10.1038/aps.2014.80
Ghasemi R, Dargahi L, Haeri A, Moosavi M, Mohamed Z, Ahmadiani A (2013) Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders. Mol Neurobiol 47(3):1045–1065. https://doi.org/10.1007/s12035-013-8404-z
Zhande R, Zhang W, Zheng Y, Pendleton E, Li Y, Polakiewicz RD, Sun XJ (2006) Dephosphorylation by default, a potential mechanism for regulation of insulin receptor substrate-1/2, Akt, and ERK1/2. J Biol Chem 281(51):39071–39080. https://doi.org/10.1074/jbc.M605251200
Shi Y (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139:468–484. https://doi.org/10.1016/j.cell.2009.10.006
Rusnak F, Mertz P (2000) Calcineurin: form and function. Physiol Rev 80(4):1483–1521. https://doi.org/10.1152/physrev.2000.80.4.1483
Hinds TD Jr, Sánchez ER (2008) Protein phosphatase 5. Int J Biochem Cell Biol 40(11):2358–2362. https://doi.org/10.1016/j.biocel.2007.08.010
Davies TH, Ning Y-M, Sánchez ER (2005) Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 44(6):2030–2038. https://doi.org/10.1021/bi048503v
Golden T, Swingle M, Honkanen RE (2008) The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer. Cancer Metastasis Rev 27(2):169–178. https://doi.org/10.1007/s10555-008-9125-z
Kutuzov MA, Bennett N, Andreeva AV (2001) Interaction of plant protein Ser/Thr phosphatase PP7 with calmodulin. Biochem Biophys Res Commun 289(2):634–640. https://doi.org/10.1006/bbrc.2001.6020
Lu G, Wang Y (2008) Functional diversity of mammalian type 2C protein phosphatase isoforms: new tales from an old family. Clin Exp Pharmacol Physiol 35(2):107–112. https://doi.org/10.1111/j.1440-1681.2007.04843.x
Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418(3):475–489
Jeong DG, Wei CH, Ku B, Jeon TJ, Chien PN, Kim JK, Park SY, Hwang HS, Ryu SY, Park H (2014) The family-wide structure and function of human dual-specificity protein phosphatases. Acta Crystallogr D Biol Crystallogr 70(2):421–435. https://doi.org/10.1107/S1399004713029866
Bastan R, Eskandari N, Sabzghabaee AM, Manian M (2014) Serine/Threonine phosphatases: classification, roles and pharmacological regulation. Int J Immunopathol Pharmacol 27(4):473–484. https://doi.org/10.1177/039463201402700402
Seshacharyulu P, Pandey P, Datta K, Batra SK (2013) Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 335(1):9–18. https://doi.org/10.1016/j.canlet.2013.02.036
Cho US, Xu W (2007) Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445(7123):53. https://doi.org/10.1038/nature05351
Nematullah M, Hoda M, Khan F (2018) Protein phosphatase 2A: a double-faced phosphatase of cellular system and Its role in neurodegenerative disorders. Mol Neurobiol 55(2):1750–1761. https://doi.org/10.1007/s12035-017-0444-3
Kiely M, Kiely PA (2015) PP2A: the wolf in sheep’s clothing? Cancers (Basel) 7(2):648–669. https://doi.org/10.3390/cancers7020648
Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G (2016) All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J 283(6):1004–1024. https://doi.org/10.1111/febs.13573
Francia G, Poulsom R, Hanby AM, Mitchell SD, Williams G, McKee P, Hart IR (1999) Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells. Int J Cancer 82(5):709–713
Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353(Pt 3):417–439
Janssens V, Longin S, Goris J (2008) PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 33(3):113–121. https://doi.org/10.1016/j.tibs.2007.12.004
Sents W, Ivanova E, Lambrecht C, Haesen D, Janssens V (2013) The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity. FEBS J 280(2):644–661. https://doi.org/10.1111/j.1742-4658.2012.08579.x
Ikehara T, Ikehara S, Imamura S, Shinjo F, Yasumoto T (2007) Methylation of the C-terminal leucine residue of the PP2A catalytic subunit is unnecessary for the catalytic activity and the binding of regulatory subunit (PR55/B). Biochem Biophys Res Commun 354(4):1052–1057. https://doi.org/10.1016/j.bbrc.2007.01.085
Lee JA, Pallas DC (2007) Leucine carboxyl methyltransferase-1 is necessary for normal progression through mitosis in mammalian cells. J Biol Chem 282(42):30974–30984. https://doi.org/10.1074/jbc.M704861200
Ortega-Gutierrez S, Leung D, Ficarro S, Peters EC, Cravatt BF (2008) Targeted disruption of the PME-1 gene causes loss of demethylated PP2A and perinatal lethality in mice. PLoS One 3(7):e2486. https://doi.org/10.1371/journal.pone.0002486
Longin S, Jordens J, Martens E, Stevens I, Janssens V, Rondelez E, De Baere I, Derua R, Waelkens E, Goris J, Van Hoof C (2004) An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem J 380(Pt 1):111–119. https://doi.org/10.1042/BJ20031643
Guo F, Stanevich V, Wlodarchak N, Sengupta R, Jiang L, Satyshur KA, Xing Y (2014) Structural basis of PP2A activation by PTPA, an ATP-dependent activation chaperone. Cell Res 24(2):190–203. https://doi.org/10.1038/cr.2013.138
Luo Y, Nie YJ, Shi HR, Ni ZF, Wang Q, Wang JZ (1833) Liu GP (2013) PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B. Biochim Biophys Acta 5:1235–1243. https://doi.org/10.1016/j.bbamcr.2013.02.005
Stanevich V, Jiang L, Satyshur KA, Li Y, Jeffrey PD, Li Z, Menden P, Semmelhack MF, Xing Y (2011) The structural basis for tight control of PP2A methylation and function by LCMT-1. Mol Cell 41(3):331–342. https://doi.org/10.1016/j.molcel.2010.12.030
Silverstein AM, Barrow CA, Davis AJ, Mumby MC (2002) Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci USA 99(7):4221–4226. https://doi.org/10.1073/pnas.072071699
Kong M, Ditsworth D, Lindsten T, Thompson CB (2009) Alpha4 is an essential regulator of PP2A phosphatase activity. Mol Cell 36(1):51–60. https://doi.org/10.1016/j.molcel.2009.09.025
McConnell JL, Gomez RJ, McCorvey LR, Law BK, Wadzinski BE (2007) Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway. Oncogene 26(41):6021–6030. https://doi.org/10.1038/sj.onc.1210406
Smetana JH, Zanchin NI (2007) Interaction analysis of the heterotrimer formed by the phosphatase 2A catalytic subunit, alpha4 and the mammalian ortholog of yeast Tip41 (TIPRL). FEBS J 274(22):5891–5904. https://doi.org/10.1111/j.1742-4658.2007.06112.x
Li M, Guo H, Damuni Z (1995) Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34(6):1988–1996. https://doi.org/10.1021/bi00006a020
Hino H, Takaki K, Mochida S (2015) Inhibitor-1 and -2 of PP2A have preference between PP2A complexes. Biochem Biophys Res Commun 467(2):297–302. https://doi.org/10.1016/j.bbrc.2015.09.168
Gharbi-Ayachi A, Labbe JC, Burgess A, Vigneron S, Strub JM, Brioudes E, Van-Dorsselaer A, Castro A, Lorca T (2010) The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science 330(6011):1673–1677. https://doi.org/10.1126/science.1197048
Mochida S, Maslen SL, Skehel M, Hunt T (2010) Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science 330(6011):1670–1673. https://doi.org/10.1126/science.1195689
Porter IM, Schleicher K, Porter M, Swedlow JR (2013) Bod1 regulates protein phosphatase 2A at mitotic kinetochores. Nat Commun 4:2677. https://doi.org/10.1038/ncomms3677
Kumar A, Singh A, Ekavali (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 67(2):195–203. https://doi.org/10.1016/j.pharep.2014.09.004
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5(1):64–74. https://doi.org/10.1016/S1474-4422(05)70284-2
Gratuze M, Planel E (2017) Regulation of brain insulin signaling: a new function for tau. Rockefeller University Press, New York City. https://doi.org/10.1084/jem.20170979
Suzanne M (2017) Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer’s disease. Drugs 77(1):47–65. https://doi.org/10.1007/s40265-016-0674-0
Sontag JM, Sontag E (2014) Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front Mol Neurosci 7:16. https://doi.org/10.3389/fnmol.2014.00016
Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61(3):921–927. https://doi.org/10.1111/j.1471-4159.1993.tb03603.x
Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL 3rd (2004) Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63(4):287–301. https://doi.org/10.1093/jnen/63.4.287
Sontag J-M, Wasek B, Taleski G, Smith J, Arning E, Sontag E, Bottiglieri T (2014) Altered protein phosphatase 2A methylation and Tau phosphorylation in the young and aged brain of methylenetetrahydrofolate reductase (MTHFR) deficient mice. Front Aging Neurosci 6:214. https://doi.org/10.3389/fnagi.2014.00214
Arif M, Wei J, Zhang Q, Liu F, Basurto-Islas G, Grundke-Iqbal I, Iqbal K (2014) Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau. J Biol Chem 289(40):27677–27691. https://doi.org/10.1074/jbc.M114.565358
Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268(32):24374–24384
Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F (2010) PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 19(4):1221–1229. https://doi.org/10.3233/JAD-2010-1317
Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Terro F (2013) Tau protein phosphatases in Alzheimer’s disease: the leading role of PP2A. Ageing Res Rev 12(1):39–49. https://doi.org/10.1016/j.arr.2012.06.008
Hu W, Wu F, Zhang Y, Gong CX, Iqbal K, Liu F (2017) Expression of tau pathology-related proteins in different brain regions: a molecular basis of tau pathogenesis. Front Aging Neurosci 9:311. https://doi.org/10.3389/fnagi.2017.00311
Iqbal K, Gong CX, Liu F (2014) Microtubule-associated protein tau as a therapeutic target in Alzheimer’s disease. Expert Opin Ther Targets 18(3):307–318. https://doi.org/10.1517/14728222.2014.870156
Yu UY, Yoo BC, Ahn JH (2014) Regulatory B subunits of protein phosphatase 2A are involved in site-specific regulation of tau protein phosphorylation. Korean J Physiol Pharmacol 18(2):155–161. https://doi.org/10.4196/kjpp.2014.18.2.155
Schweiger S, Matthes F, Posey K, Kickstein E, Weber S, Hettich MM, Pfurtscheller S, Ehninger D, Schneider R, Krauss S (2017) Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Sci Rep 7(1):13753. https://doi.org/10.1038/s41598-017-12974-4
Yang CC, Kuai XX, Gao WB, Yu JC, Wang Q, Li L, Zhang L (2016) Morroniside-induced PP2A activation antagonizes tau hyperphosphorylation in a cellular model of neurodegeneration. J Alzheimers Dis 51(1):33–44. https://doi.org/10.3233/JAD-150728
Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269(20):14566–14574
Hagen T, Di Daniel E, Culbert AA, Reith AD (2002) Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells. J Biol Chem. https://doi.org/10.1074/jbc.m201364200
Wang Y, Yang R, Gu J, Yin X, Jin N, Xie S, Wang Y, Chang H, Qian W, Shi J (2015) Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging 36(1):188–200. https://doi.org/10.1016/j.neurobiolaging.2014.07.035
Millward TA, Zolnierowicz S, Hemmings BA (1999) Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24(5):186–191. https://doi.org/10.1016/S0968-0004(99)01375-4
Kins S, Kurosinski P, Nitsch RM, Gotz J (2003) Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 163(3):833–843. https://doi.org/10.1016/S0002-9440(10)63444-X
O’Brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 34:185–204. https://doi.org/10.1146/annurev-neuro-061010-113613
Tian Q, Wang J (2002) Role of serine/threonine protein phosphatase in Alzheimer’s disease. Neurosignals 11(5):262–269. https://doi.org/10.1159/000067425
Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH (2003) APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163(1):83–95. https://doi.org/10.1083/jcb.200301115
Colombo A, Bastone A, Ploia C, Sclip A, Salmona M, Forloni G, Borsello T (2009) JNK regulates APP cleavage and degradation in a model of Alzheimer’s disease. Neurobiol Dis 33(3):518–525. https://doi.org/10.1016/j.nbd.2008.12.014
Zhang JW, Jing LJ, Jian G, Dong GC (2015) Mechanism of protein phosphatase-2Aregulating phosphorylation of amyloid precursor proteosome and Abeta generation. Bratisl Lek Listy 116(3):184–190
Braithwaite SP, Schmid RS, He DN, Sung ML, Cho S, Resnick L, Monaghan MM, Hirst WD, Essrich C, Reinhart PH, Lo DC (2010) Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer’s disease. Neurobiol Dis 39(3):311–317. https://doi.org/10.1016/j.nbd.2010.04.015
Eichhorn PJ, Creyghton MP, Bernards R (2009) Protein phosphatase 2A regulatory subunits and cancer. BBA Rev Cancer 1795(1):1–15. https://doi.org/10.1016/j.bbcan.2008.05.005
Perrotti D, Neviani P (2013) Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 14(6):e229–e238. https://doi.org/10.1016/S1470-2045(12)70558-2
Jin Z, Wallace L, Harper SQ, Yang J (2010) PP2A: B56ε, a substrate of caspase-3, regulates p53-dependent and-independent apoptosis during development. JBC M110:169581. https://doi.org/10.1074/jbc.M110.169581
Deng X, Gao F, May WS (2009) Protein phosphatase 2A inactivates Bcl2′s antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding. Blood 113(2):422–428. https://doi.org/10.1182/blood-2008-06-165134
Van Hoof C, Goris J (2003) Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. BBA Mol Cell Res 1640(2–3):97–104. https://doi.org/10.1016/s0167-4889(03)00029-6
Shang S, Hua F, Hu ZW (2017) The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8(20):33972–33989. https://doi.org/10.18632/oncotarget.15687
Donmez HG, Demirezen S, Beksac MS (2016) The relationship between beta-catenin and apoptosis: a cytological and immunocytochemical examination. Tissue Cell 48(3):160–167. https://doi.org/10.1016/j.tice.2016.04.001
Yao W, Zou HJ, Sun D, Ren SQ (2013) Abeta induces acute depression of excitatory glutamatergic synaptic transmission through distinct phosphatase-dependent mechanisms in rat CA1 pyramidal neurons. Brain Res 1515:88–97. https://doi.org/10.1016/j.brainres.2013.03.049
Theendakara V, Bredesen DE, Rao RV (2017) Downregulation of protein phosphatase 2A by apolipoprotein E: implications for Alzheimer’s disease. Mol Cell Neurosci 83:83–91. https://doi.org/10.1016/j.mcn.2017.07.002
Tanimukai H, Grundke-Iqbal I, Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease. Am J Pathol 166(6):1761–1771. https://doi.org/10.1016/S0002-9440(10)62486-8
Basurto-Islas G, Grundke-Iqbal I, Tung YC, Liu F, Iqbal K (2013) Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease. J Biol Chem 288(24):17495–17507. https://doi.org/10.1074/jbc.M112.446070
Chasseigneaux S, Clamagirand C, Huguet L, Gorisse-Hussonnois L, Rose C, Allinquant B (2014) Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A. BMC Neurosci 15:82. https://doi.org/10.1186/1471-2202-15-82
Sun XY, Wei YP, Xiong Y, Wang XC, Xie AJ, Wang XL, Yang Y, Wang Q, Lu YM, Liu R, Wang JZ (2012) Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2A (PP2A). J Biol Chem 287(14):11174–11182. https://doi.org/10.1074/jbc.M111.309070
Xiong Y, Jing XP, Zhou XW, Wang XL, Yang Y, Sun XY, Qiu M, Cao FY, Lu YM, Liu R, Wang JZ (2013) Zinc induces protein phosphatase 2A inactivation and tau hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation. Neurobiol Aging 34(3):745–756. https://doi.org/10.1016/j.neurobiolaging.2012.07.003
Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, Raymond AA, Dargahi L, Ghasemi R, Ahmadiani A (2015) Glycogen synthase kinase-3 beta (GSK-3β) signaling: implications for Parkinson’s disease. Pharmacol Res 97:16–26. https://doi.org/10.1016/j.phrs.2015.03.010
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164. https://doi.org/10.1038/ncb748
Waxman EA, Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol 67(5):402–416. https://doi.org/10.1097/NEN.0b013e31816fc995
Taymans JM, Baekelandt V (2014) Phosphatases of alpha-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Front Genet 5:382. https://doi.org/10.3389/fgene.2014.00382
Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM (2011) Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J Neurosci 31(19):6963–6971. https://doi.org/10.1523/JNEUROSCI.6513-10.2011
Park HJ, Lee KW, Park ES, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM (2016) Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann Clin Transl Neurol 3(10):769–780. https://doi.org/10.1002/acn3.337
Wu J, Lou H, Alerte TN, Stachowski EK, Chen J, Singleton AB, Hamilton RL, Perez RG (2012) Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience 207:288–297. https://doi.org/10.1016/j.neuroscience.2012.01.028
Tian H, Lu Y, Liu J, Liu W, Lu L, Duan C, Gao G, Yang H (2018) Leucine carboxyl methyltransferase downregulation and protein phosphatase methylesterase upregulation contribute toward the inhibition of protein phosphatase 2A by alpha-synuclein. Front Aging Neurosci 10:173. https://doi.org/10.3389/fnagi.2018.00173
Arif M, Kazim SF, Grundke-Iqbal I, Garruto RM, Iqbal K (2014) Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci USA 111(3):1144–1149. https://doi.org/10.1073/pnas.1322614111
Jazvinscak Jembrek M, Hof PR, Simic G (2015) Ceramides in Alzheimer’s disease: key mediators of neuronal apoptosis induced by oxidative stress and abeta accumulation. Oxid Med Cell Longev 2015:346783. https://doi.org/10.1155/2015/346783
Beg M, Srivastava A, Shankar K, Varshney S, Rajan S, Gupta A, Kumar D, Gaikwad AN (2016) PPP2R5B, a regulatory subunit of PP2A, contributes to adipocyte insulin resistance. Mol Cell Endocrinol 437:97–107. https://doi.org/10.1016/j.mce.2016.08.016
Jun HS, Hwang K, Kim Y, Park T (2008) High-fat diet alters PP2A, TC10, and CIP4 expression in visceral adipose tissue of rats. Obesity (Silver Spring) 16(6):1226–1231. https://doi.org/10.1038/oby.2008.220
Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C (2001) A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50(10):2210–2218. https://doi.org/10.2337/DIABETES.50.10.2210
Srinivasan M, Begum N (1994) Regulation of protein phosphatase 1 and 2A activities by insulin during myogenesis in rat skeletal muscle cells in culture. J Biol Chem 269(17):12514–12520
Begum N, Ragolia L (1996) cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. J Biol Chem 271(49):31166–31171. https://doi.org/10.1074/jbc.271.49.31166
Hojlund K, Poulsen M, Staehr P, Brusgaard K, Beck-Nielsen H (2002) Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes. Eur J Clin Invest 32(12):918–923. https://doi.org/10.1046/j.1365-2362.2002.01098.x
Vazquez-Carballo A, Ceperuelo-Mallafre V, Chacon MR, Maymo-Masip E, Lorenzo M, Porras A, Vendrell J, Fernandez-Veledo S (2013) TWEAK prevents TNF-alpha-induced insulin resistance through PP2A activation in human adipocytes. Am J Physiol Endocrinol Metab 305(1):E101–E112. https://doi.org/10.1152/ajpendo.00589.2012
Carlson CJ, White MF, Rondinone CM (2004) Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem Biophys Res Commun 316(2):533–539. https://doi.org/10.1016/j.bbrc.2004.02.082
Hartley D, Cooper GM (2002) Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem 85(2):304–314. https://doi.org/10.1002/jcb.10135
Mandavia C, Sowers JR (2012) Phosphoprotein phosphatase PP2A regulation of insulin receptor substrate 1 and insulin metabolic signaling. Cardiorenal Med 2(4):308–313. https://doi.org/10.1159/000343889
Galbo T, Perry RJ, Nishimura E, Samuel VT, Quistorff B, Shulman GI (2013) PP2A inhibition results in hepatic insulin resistance despite Akt2 activation. Aging (Albany NY) 5(10):770–781. https://doi.org/10.18632/aging.100611
Gratuze M, Julien J, Petry FR, Morin F, Planel E (2017) Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer’s disease-like tau pathology. Sci Rep 7:46359. https://doi.org/10.1038/srep46359
Oaks J, Ogretmen B (2014) Regulation of PP2A by sphingolipid metabolism and signaling. Front Oncol 4:388. https://doi.org/10.3389/fonc.2014.00388
Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J (2015) PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget 6(6):4299. https://doi.org/10.18632/oncotarget.3012
Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, Madoz-Gúrpide J, Rojo F, García-Foncillas J (2015) Activation of the tumor suppressor PP2A emerges as a potential therapeutic strategy for treating prostate cancer. Mar Drugs 13(6):3276–3286. https://doi.org/10.3390/md13063276
Mani R, Mao Y, Frissora FW, Chiang C-L, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X (2015) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29(2):346. https://doi.org/10.1038/leu.2014.199
Zonta F, Pagano MA, Trentin L, Tibaldi E, Frezzato F, Trimarco V, Facco M, Zagotto G, Pavan V, Ribaudo G, Bordin L, Semenzato G, Brunati AM (2015) Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood 125(24):3747–3755. https://doi.org/10.1182/blood-2014-12-619155
Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer’s disease: an update. Annu Rev Neurosci 37:79–100. https://doi.org/10.1146/annurev-neuro-071013-014300
O’Connor CM, Perl A, Leonard D, Sangodkar J, Narla G (2018) Therapeutic targeting of PP2A. Int J Biochem Cell Biol 96:182–193. https://doi.org/10.1016/j.biocel.2017.10.008
Vitek M, Christensen D, Wilcock D, Davis J, Van Nostrand W, Li F, Colton C (2012) APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer’s disease transgenics. Neurodegener Dis 10(1–4):122–126. https://doi.org/10.1159/000334914
Ghosal K, Stathopoulos A, Thomas D, Phenis D, Vitek MP, Pimplikar SW (2013) The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer’s disease-like pathological features. Neurodegener Dis 12(1):51–58. https://doi.org/10.1159/000341299
Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F, Colton CA, Vitek MP (2011) Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 186(4):2535–2542. https://doi.org/10.4049/jimmunol.1002847
Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears RC, Vitek MP, Odero MD, Christensen DJ (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2575:2013. https://doi.org/10.1158/1078-0432.CCR-13-2575
Liu Z, Ma L, Zhou GB (2011) The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules 16(6):5283–5297. https://doi.org/10.3390/molecules16065283
Liu Z, Ma L, Wen Z-S, Hu Z, Wu F-Q, Li W, Liu J, Zhou G-B (2013) Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis 35(4):905–914. https://doi.org/10.1093/carcin/bgt395
Wu J, Ding M, Mao N, Wu Y, Wang C, Yuan J, Miao X, Li J, Shi Z (2017) Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway. J Pharm Sci 134(1):22–28. https://doi.org/10.1016/j.jphs.2016.12.007
Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Seminars in oncology, vol 4. Elsevier, Oxfrod, pp 369–385. https://doi.org/10.1053/j.seminoncol.2006.04.003
Chen K-F, Pao K-C, Su J-C, Chou Y-C, Liu C-Y, Chen H-J, Huang J-W, Kim I, Shiau C-W (2012) Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem 20(20):6144–6153. https://doi.org/10.1016/j.bmc.2012.08.039
Liu C-Y, Huang T-T, Huang C-T, Hu M-H, Wang D-S, Wang W-L, Tsai W-C, Lee C-H, Lau K-Y, Yang H-P (2017) EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Eur J Cancer 72:112–123. https://doi.org/10.1016/j.ejca.2016.11.012
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL (2010) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29(47):6257–6266. https://doi.org/10.1038/onc.2010.357
Ding Y, Wang Y, Ju S, Wu X, Zhu W, Shi F, Mao L (2014) Role of CIP2A in the antitumor effect of bortezomib in colon cancer. Mol Med Rep 10(1):387–392. https://doi.org/10.3892/mmr.2014.2173
Miao F, Yang X-J, Zhou L, Hu H-J, Zheng F, Ding X-D, Sun D-M, Zhou C-D, Sun W (2011) Structural modification of sanguinarine and chelerythrine and their antibacterial activity. Nat Prod Res 25(9):863–875. https://doi.org/10.1080/14786419.2010.482055
W-g Li, F-y Dai, Y-x Cheng, G-f Yin, J-l Bi, D-p Li (2013) Identification of porcine reproductive and respiratory syndrome virus inhibitors through an oriented screening on natural products. Chem Res Chin Univ 29(2):290–293. https://doi.org/10.1007/s40242-013-2300-y
Liu Z, Ma L, Wen ZS, Cheng YX, Zhou GB (2014) Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells. ACS Med Chem Lett 5(2):113–118. https://doi.org/10.1021/ml400341k
Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schurer SC, Nomura DK, Rosen H, Fu GC, Cravatt BF (2011) Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci USA 108(17):6811–6816. https://doi.org/10.1073/pnas.1015248108
Bachovchin DA, Zuhl AM, Speers AE, Wolfe MR, Weerapana E, Brown SJ, Rosen H, Cravatt BF (2011) Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem 54(14):5229–5236. https://doi.org/10.1021/jm200502u
Guénin S, Schwartz L, Morvan D, Steyaert JM, Poignet A, Madelmont JC, Demidem A (2008) PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int J Oncol 32(1):49–57. https://doi.org/10.3892/ijo.32.1.49
Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K (2003) Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc Natl Acad Sci USA 100(9):5107–5112. https://doi.org/10.1073/pnas.0730817100
Schabel FM Jr (1976) Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 60(6):665–698
Seamon KB, Padgett W, Daly JW (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 78(6):3363–3367. https://doi.org/10.1073/pnas.78.6.3363
Cristobal I, Garcia-Orti L, Cirauqui C, Alonso M, Calasanz M, Odero M (2011) PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25(4):606. https://doi.org/10.1038/leu.2010.294
Cristóbal I, Rincón R, Manso R, Madoz-Gúrpide J, Caramés C, del Puerto-Nevado L, Rojo F (1842) García-Foncillas J (2014) Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. BBA Mol Basis Dis 9:1823–1829. https://doi.org/10.1016/j.bbadis.2014.06.032
Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, Chen CS (2009) alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 30(7):1125–1131. https://doi.org/10.1093/carcin/bgp112
Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, Gellert N, Mayne GC, Olejnicka B, Negre-Salvayre A, Sticha M, Coffey RJ, Weber C (2001) Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 15(2):403–415. https://doi.org/10.1096/fj.00-0251com
Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC (2014) Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest 124(2):644–655. https://doi.org/10.1172/JCI65093
Fujiki H, Sueoka E, Watanabe T, Suganuma M (2018) The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers. J Cancer Res Clin Oncol 144(12):2339–2349. https://doi.org/10.1007/s00432-018-2765-7
Swingle M, Ni L, Honkanen RE (2007) Small-Molecule Inhibitors of Ser/Thr Protein Phosphatases. In: Moorhead G (ed) Protein Phosphatase Protocols. Springer New York, Totowa, NJ, pp 23-38. https://doi.org/10.1385/1-59745-267-x:23
Honkanen R, Golden T (2002) Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem 9(22):2055–2075. https://doi.org/10.2174/0929867023368836
Prickett TD, Brautigan DL (2006) The α4 regulatory subunit exerts opposing allosteric effects on protein phosphatases PP6 and PP2A. J Biol Chem 281(41):30503–30511. https://doi.org/10.1074/jbc.M601054200
Walsh AH, Cheng A, Honkanen RE (1997) Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Lett 416(3):230–234. https://doi.org/10.1016/S0014-5793(97)01210-6
Twiner MJ, Doucette GJ, Pang Y, Fang C, Forsyth CJ, Miles CO (2016) Structure-activity relationship studies using natural and synthetic okadaic acid/dinophysistoxin toxins. Mar Drugs 14(11):207. https://doi.org/10.3390/md14110207
Hong CS, Ho W, Zhang C, Yang C, Elder JB, Zhuang Z (2015) LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther 16(6):821–833. https://doi.org/10.1080/15384047.2015.1040961
Azad N, Rasoolijazi H, Joghataie MT, Soleimani S (2011) Neuroprotective effects of carnosic acid in an experimental model of Alzheimer’s disease in rats. Cell J (Yakhteh) 13(1):39
Lipina C, Hundal HS (2014) Carnosic acid stimulates glucose uptake in skeletal muscle cells via a PME-1/PP2A/PKB signalling axis. Cell Signal 26(11):2343–2349. https://doi.org/10.1016/j.cellsig.2014.07.022
Kar S, Palit S, Ball WB, Das PK (2012) Carnosic acid modulates Akt/IKK/NF-κB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 17(7):735–747. https://doi.org/10.1007/s10495-012-0715-4
Kolupaeva V, Daempfling L, Basilico C (2013) The B55alpha regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes. Mol Cell Biol 33(15):2865–2878. https://doi.org/10.1128/MCB.01730-12
Yabe R, Fujiwara N, Mizuno T, Usui T, Ohama T, Sato K (2014) Characterization of SET/I2PP2A isoforms in dogs. J Vet Med Sci 76(9):1235–1240. https://doi.org/10.1292/jvms.14-0209
Zhou H, Luo W, Zeng C, Zhang Y, Wang L, Yao W, Nie C (2017) PP2A mediates apoptosis or autophagic cell death in multiple myeloma cell lines. Oncotarget 8(46):80770–80789. https://doi.org/10.18632/oncotarget.20415
Suprynowicz FA, Kamonjoh CM, Krawczyk E, Agarwal S, Wellstein A, Agboke FA, Choudhury S, Liu X, Schlegel R (2017) Conditional cell reprogramming involves non-canonical beta-catenin activation and mTOR-mediated inactivation of Akt. PLoS One 12(7):e0180897. https://doi.org/10.1371/journal.pone.0180897
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O’Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma’Ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G (2017) Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Investign 127(6):2081–2090. https://doi.org/10.1172/JCI89548
Jin Z, Mei W, Strack S, Jia J, Yang J (2011) The antagonistic action of B56-containing protein phosphatase 2As and casein kinase 2 controls the phosphorylation and Gli turnover function of Daz interacting protein 1. Journal of Biological Chemistry 286 (42):jbc. M111. 274761. https://doi.org/10.1074/jbc.m111.274761
Stanevich V, Zheng A, Guo F, Jiang L, Wlodarchak N, Xing Y (2014) Mechanisms of the scaffold subunit in facilitating protein phosphatase 2A methylation. PLoS One 9(1):e86955. https://doi.org/10.1371/journal.pone.0086955
Lu S, Yao Y, Xu G, Zhou C, Zhang Y, Sun J, Jiang R, Shao Q, Chen Y (2018) CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis 9(6):646. https://doi.org/10.1038/s41419-018-0681-z
Longin S, Jordens J, Martens E, Stevens I, Janssens V, Rondelez E, De Baere I, Derua R, Waelkens E, Goris J (2004) An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem J 380(1):111–119. https://doi.org/10.1042/BJ20031643
Liu XP, Zheng HY, Qu M, Zhang Y, Cao FY, Wang Q, Ke D, Liu GP, Wang JZ (2012) Upregulation of astrocytes protein phosphatase-2A stimulates astrocytes migration via inhibiting p38 MAPK in tg2576 mice. Glia 60(9):1279–1288. https://doi.org/10.1002/glia.22347
Lorenz U (2011) Protein tyrosine phosphatase assays. Curr Protoc Immunol Chapter 11 (1):Unit 11 17. https://doi.org/10.1002/0471142735.im1107s93
Rudrabhatla P, Albers W, Pant HC (2009) Peptidyl-prolyl isomerase 1 regulates protein phosphatase 2A-mediated topographic phosphorylation of neurofilament proteins. J Neurosci 29(47):14869–14880. https://doi.org/10.1523/JNEUROSCI.4469-09.2009
Rahman A, Brew BJ, Guillemin GJ (2011) Lead dysregulates serine/threonine protein phosphatases in human neurons. Neurochem Res 36(2):195–204. https://doi.org/10.1007/s11064-010-0300-6
Acknowledgements
The authors are thankful to neuroscience research center and neurophysiology research center Shahid Beheshti University of Medical science for supporting this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Javadpour, P., Dargahi, L., Ahmadiani, A. et al. To be or not to be: PP2A as a dual player in CNS functions, its role in neurodegeneration, and its interaction with brain insulin signaling. Cell. Mol. Life Sci. 76, 2277–2297 (2019). https://doi.org/10.1007/s00018-019-03063-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-019-03063-y